Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome Therapeutics and Hetero Labs agreed to settle to resolve patent litigation claims. The litigation, which is pending in a New Jersey district court, resulted from Hetero submitting an ...

Viatris Inc. , a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new ...

Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") , a Canadian healthcare and clinical stage drug development company, is pleased to announce a non-brokered private placement for gross ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Axsome’s total product revenues increased by 62% year-over-year, driven by strong sales of Auvelity and Sunosi. H.C. Wainwright analysts lowered their price target for Axsome to $180 from $200, ...

Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system disorders, today announced that it has entered into a $570 million term loan and ...

The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI, AUVELITY, and SYMBRAVO products and the success of the ...